On June 10, CARsgen Therapeutics rose 5.72% in regular trading, trading at HK$15.99/share, with trading volume of HK$61.78 million.

The rally comes amid surging enthusiasm in the in vivo CAR-T therapy sector. Recent industry data revealed breakthrough clinical results from multiple in vivo CAR-T programs, including KLN-1010 achieving 100% overall response rate with all 18 evaluable patients reaching MRD-negative status, and LB2501 demonstrating 100% ORR and 83.3% complete remission in its dose-level-2 cohort. Both programs utilize lentiviral vector technology, the same platform underpinning CARsgen's proprietary CARvivo program KJ-C2529, which targets CD19/CD20 for relapsed/refractory B-NHL and is planned to enter investigator-initiated trials this year.

Additionally, southbound capital has been consistently accumulating shares, with net purchases of 27 million shares over the past 20 trading days, bringing southbound holdings to 27.16% of outstanding shares. This persistent institutional buying provides further support to the stock price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)